Market Overview

UPDATE: Jefferies Raises PT to $20 on Arena Pharmaceuticals on Belviq FDA Aproval

Related ARNA
Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr
Benzinga's Top #PreMarket Losers

Jefferies reiterates its Buy rating on Arena Pharmaceuticals (NASDAQ: ARNA) and raises its price target from $9 to $20.

Jefferies says, "Belviq has been approved by the FDA. We believe the Belviq label is a major positive for ARNA, as it lacks a restrictive REMS or cardiovascular monitoring requirements. We remain buyers of ARNA and are raising our price target from $9 to $20."

ARNA closed at $11.39 on Wednesday.

Posted-In: JefferiesAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Most Popular

Related Articles (ARNA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free